MedTrace Logo

Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers

NCT02348203 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2022-06-02

Study results available
· View outcomes & findings →

Summary

This randomized phase II trial studies the effects of aspirin and zileuton on genes related to tobacco use in current smokers. Aspirin and zileuton may interfere with genes related to tobacco use and may be useful in preventing lung cancer in current smokers.

Conditions

  • Tobacco Use Disorder

Interventions

DRUG

Aspirin

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo Administration

Given aspirin placebo PO

OTHER

Placebo Administration

Given zileuton placebo PO

DRUG

Zileuton

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Linda L Garland · The University of Arizona Medical Center-University Campus

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-13
Primary Completion
2019-02-22
Completion
2021-03-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02348203 on ClinicalTrials.gov